Recent Posts
News•Feb 17, 2026
VB Spine to Acquire Xvision Spine System From Augmedics
VB Spine has signed a definitive agreement to acquire Augmedics' xvision Spine System, adding augmented reality navigation to its enhanced visualization suite. The FDA‑cleared platform, already used in nearly 13,000 procedures, offers direct patient visualization, workflow efficiency, and reduced radiation exposure. This acquisition follows VB Spine's recent purchase of the SpineHawk intra‑operative visualization platform, creating a combined portfolio that spans open and minimally invasive spine surgery. Integration aims to leverage VB Spine's implant scale to unlock the full potential of AR navigation.
By Hospital Management
News•Feb 17, 2026
CStone Secures FDA Clearance to Begin CS2009 Phase II Trial
CStone Pharmaceuticals has secured FDA clearance for its investigational new drug application, allowing the launch of a Phase II trial of CS2009, a trispecific antibody that simultaneously targets PD‑1, VEGFA and CTLA‑4. The global study uses a parallel, multi‑cohort expansion design...
By Hospital Management
News•Feb 17, 2026
ExCellThera Secures German NUB Status 1 Listing for Zemcelpro
ExCellThera and its subsidiary Cordex Biologics have secured a Status 1 listing under Germany’s NUB programme for their cell therapy Zemcelpro (dorocubicel). The therapy, which received conditional marketing authorisation from the European Commission, targets adults with haematological malignancies lacking suitable donor...
By Hospital Management
Deals•Feb 17, 2026
VB Spine to Acquire Augmedics' Xvision Spine System
VB Spine announced it has signed a definitive agreement to acquire Augmedics' xvision Spine System, adding augmented reality navigation to its visualization portfolio. The transaction, pending regulatory approval, is expected to close in the coming weeks and follows VB Spine's...
Hospital Management
News•Feb 16, 2026
Novartis Reports Final Data of ALIGN Trial in IgAN
Novartis released final Phase III ALIGN data showing its oral endothelin‑A antagonist Vanrafia (atrasentan) slowed kidney function decline in adults with IgA nephropathy. The double‑blind, placebo‑controlled trial enrolled 340 biopsy‑confirmed patients who continued optimized RAS inhibition, delivering a 2.39 ml/min/1.73 m² advantage in...
By Hospital Management
News•Feb 16, 2026
Medtronic Secures FDA Approval for Stealth AXiS Spine Robotics Platform
Medtronic has secured FDA clearance for its Stealth AXiS spine‑surgery robotics platform, an integrated solution that combines robotics, planning and navigation in a single workflow. The system features LiveAlign segmental tracking, delivering real‑time visualization of anatomical movement and reducing the need...
By Hospital Management
News•Feb 16, 2026
Immunic Secures $400m Fund to Support Commercial-Stage Development
Immunic announced an oversubscribed private placement that could raise up to $400 million, led by BVF Partners and other institutional investors. The capital will fund the completion of the Phase III ENSURE trial of vidofludimus calcium in relapsing multiple sclerosis, with topline...
By Hospital Management
Deals•Feb 16, 2026
Immunic Raises up to $400M in Oversubscribed Private Placement
Immunic announced an oversubscribed private placement of up to $400 million, led by BVF Partners and joined by Avidity Partners, OrbiMed, Trails Edge Capital Partners, TCGX and Vivo Capital. The funds will support Phase III ENSURE studies for its multiple sclerosis therapy...
Hospital Management
News•Feb 13, 2026
Philips Unveils New InkSpace Snuggle Coil for Paediatric Imaging
Philips has launched the InkSpace Imaging Snuggle, a flexible paediatric body array coil for its 3.0 T MRI platforms. The blanket‑like, lightweight design wraps around children, aiming to reduce anxiety and improve comfort. Its high‑density array delivers sharp, high‑resolution images, cutting...
By Hospital Management
News•Feb 13, 2026
Lyell Doses First Patient in Phase III Trial for LBCL
Lyell Immunopharma has administered the first dose of its investigational CAR‑T therapy, ronde‑cel (LYL314), in the Phase III PiNACLE‑H2H trial for relapsed or refractory large B‑cell lymphoma. The head‑to‑head study randomizes roughly 400 patients to receive either ronde‑cel at 100 × 10⁶ cells...
By Hospital Management
Deals•Feb 12, 2026
Natus Sensory Acquires TheraB Medical to Expand Neonatal Phototherapy
Natus Sensory announced the acquisition of TheraB Medical, a U.S. developer of the SnugLit wearable phototherapy device for neonatal jaundice. The deal will broaden Natus Sensory’s newborn care portfolio and leverage TheraB’s FDA‑cleared technology to expand access across hospitals and...
Hospital Management
News•Feb 11, 2026
BioRestorative Concludes Phase II BRTX-100 Trial Enrolment for cLDD
BioRestorative Therapies announced completion of patient enrollment for its Phase II BRTX‑100 trial in chronic lumbar disc disease, enrolling 99 subjects at 15 U.S. sites. The double‑blind, sham‑controlled study randomizes participants 2:1 to receive an autologous hypoxically cultured mesenchymal stem cell...
By Hospital Management